OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients

N. Bassi, A. Ghirardello, L. Iaccarino, S. Zampieri, M. E. Rampudda, F. Atzeni, P. Sarzi-Puttini, Y. Shoenfeld, A. Doria

Research output: Contribution to journalArticle

Abstract

It has been demonstrated that atherosclerosis (ATS) is enhanced in autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in SLE patients than in general population, they do not seem to fully explain the enhanced risk. ATS has the characteristics of an autoimmune chronic disease, involving both the innate and the adaptive immunity. Moreover, it satisfies the four criteria defining an autoimmune disease, proposed by Witebsky and Rose. It has been shown that some autoantibodies, including anti-oxLDL, anti-β2GPI, anti-HSP60/65, and more recently anti-oxLDL/β2GPI, play a key role in the pathogenesis of ATS. However the role of these autoantibodies in accelerated ATS in SLE patients is still controversial. In fact, some of them seem to be proatherogenic and other protective; moreover, it has been demonstrated that induced oral tolerance has a protective role against ATS. We have recently observed that the levels of oxLDL/β2GPI antigenic complexes and their antibodies were higher in patients with SLE than in healthy subjects, but we did not find a clear association between oxLDL/β2GPI complexes and IgG or IgM anti-oxLDL/β2GPI autoantibodies and subclinical ATS in SLE patients. Many other studies are required to explain the role of autoantibodies in the pathogenesis of ATS in SLE patients, because the characteristics of SLE seem to mask their effects for atherogenesis.

Original languageEnglish
Pages (from-to)52-58
Number of pages7
JournalAutoimmunity Reviews
Volume7
Issue number1
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Systemic Lupus Erythematosus
Atherosclerosis
Autoantibodies
Autoimmune Diseases
oxidized low density lipoprotein
Adaptive Immunity
Masks
Rheumatic Diseases
Innate Immunity
Healthy Volunteers
Chronic Disease
Antibodies
Population

Keywords

  • βGPI
  • Atherosclerosis
  • HSP60/65
  • OxLDL
  • OxLDL/βGPI

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Bassi, N., Ghirardello, A., Iaccarino, L., Zampieri, S., Rampudda, M. E., Atzeni, F., ... Doria, A. (2007). OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmunity Reviews, 7(1), 52-58. https://doi.org/10.1016/j.autrev.2007.06.003

OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. / Bassi, N.; Ghirardello, A.; Iaccarino, L.; Zampieri, S.; Rampudda, M. E.; Atzeni, F.; Sarzi-Puttini, P.; Shoenfeld, Y.; Doria, A.

In: Autoimmunity Reviews, Vol. 7, No. 1, 11.2007, p. 52-58.

Research output: Contribution to journalArticle

Bassi, N, Ghirardello, A, Iaccarino, L, Zampieri, S, Rampudda, ME, Atzeni, F, Sarzi-Puttini, P, Shoenfeld, Y & Doria, A 2007, 'OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients', Autoimmunity Reviews, vol. 7, no. 1, pp. 52-58. https://doi.org/10.1016/j.autrev.2007.06.003
Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F et al. OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmunity Reviews. 2007 Nov;7(1):52-58. https://doi.org/10.1016/j.autrev.2007.06.003
Bassi, N. ; Ghirardello, A. ; Iaccarino, L. ; Zampieri, S. ; Rampudda, M. E. ; Atzeni, F. ; Sarzi-Puttini, P. ; Shoenfeld, Y. ; Doria, A. / OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. In: Autoimmunity Reviews. 2007 ; Vol. 7, No. 1. pp. 52-58.
@article{f1a8b2451b7b4ea48998d162663bd45b,
title = "OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients",
abstract = "It has been demonstrated that atherosclerosis (ATS) is enhanced in autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in SLE patients than in general population, they do not seem to fully explain the enhanced risk. ATS has the characteristics of an autoimmune chronic disease, involving both the innate and the adaptive immunity. Moreover, it satisfies the four criteria defining an autoimmune disease, proposed by Witebsky and Rose. It has been shown that some autoantibodies, including anti-oxLDL, anti-β2GPI, anti-HSP60/65, and more recently anti-oxLDL/β2GPI, play a key role in the pathogenesis of ATS. However the role of these autoantibodies in accelerated ATS in SLE patients is still controversial. In fact, some of them seem to be proatherogenic and other protective; moreover, it has been demonstrated that induced oral tolerance has a protective role against ATS. We have recently observed that the levels of oxLDL/β2GPI antigenic complexes and their antibodies were higher in patients with SLE than in healthy subjects, but we did not find a clear association between oxLDL/β2GPI complexes and IgG or IgM anti-oxLDL/β2GPI autoantibodies and subclinical ATS in SLE patients. Many other studies are required to explain the role of autoantibodies in the pathogenesis of ATS in SLE patients, because the characteristics of SLE seem to mask their effects for atherogenesis.",
keywords = "βGPI, Atherosclerosis, HSP60/65, OxLDL, OxLDL/βGPI",
author = "N. Bassi and A. Ghirardello and L. Iaccarino and S. Zampieri and Rampudda, {M. E.} and F. Atzeni and P. Sarzi-Puttini and Y. Shoenfeld and A. Doria",
year = "2007",
month = "11",
doi = "10.1016/j.autrev.2007.06.003",
language = "English",
volume = "7",
pages = "52--58",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients

AU - Bassi, N.

AU - Ghirardello, A.

AU - Iaccarino, L.

AU - Zampieri, S.

AU - Rampudda, M. E.

AU - Atzeni, F.

AU - Sarzi-Puttini, P.

AU - Shoenfeld, Y.

AU - Doria, A.

PY - 2007/11

Y1 - 2007/11

N2 - It has been demonstrated that atherosclerosis (ATS) is enhanced in autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in SLE patients than in general population, they do not seem to fully explain the enhanced risk. ATS has the characteristics of an autoimmune chronic disease, involving both the innate and the adaptive immunity. Moreover, it satisfies the four criteria defining an autoimmune disease, proposed by Witebsky and Rose. It has been shown that some autoantibodies, including anti-oxLDL, anti-β2GPI, anti-HSP60/65, and more recently anti-oxLDL/β2GPI, play a key role in the pathogenesis of ATS. However the role of these autoantibodies in accelerated ATS in SLE patients is still controversial. In fact, some of them seem to be proatherogenic and other protective; moreover, it has been demonstrated that induced oral tolerance has a protective role against ATS. We have recently observed that the levels of oxLDL/β2GPI antigenic complexes and their antibodies were higher in patients with SLE than in healthy subjects, but we did not find a clear association between oxLDL/β2GPI complexes and IgG or IgM anti-oxLDL/β2GPI autoantibodies and subclinical ATS in SLE patients. Many other studies are required to explain the role of autoantibodies in the pathogenesis of ATS in SLE patients, because the characteristics of SLE seem to mask their effects for atherogenesis.

AB - It has been demonstrated that atherosclerosis (ATS) is enhanced in autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in SLE patients than in general population, they do not seem to fully explain the enhanced risk. ATS has the characteristics of an autoimmune chronic disease, involving both the innate and the adaptive immunity. Moreover, it satisfies the four criteria defining an autoimmune disease, proposed by Witebsky and Rose. It has been shown that some autoantibodies, including anti-oxLDL, anti-β2GPI, anti-HSP60/65, and more recently anti-oxLDL/β2GPI, play a key role in the pathogenesis of ATS. However the role of these autoantibodies in accelerated ATS in SLE patients is still controversial. In fact, some of them seem to be proatherogenic and other protective; moreover, it has been demonstrated that induced oral tolerance has a protective role against ATS. We have recently observed that the levels of oxLDL/β2GPI antigenic complexes and their antibodies were higher in patients with SLE than in healthy subjects, but we did not find a clear association between oxLDL/β2GPI complexes and IgG or IgM anti-oxLDL/β2GPI autoantibodies and subclinical ATS in SLE patients. Many other studies are required to explain the role of autoantibodies in the pathogenesis of ATS in SLE patients, because the characteristics of SLE seem to mask their effects for atherogenesis.

KW - βGPI

KW - Atherosclerosis

KW - HSP60/65

KW - OxLDL

KW - OxLDL/βGPI

UR - http://www.scopus.com/inward/record.url?scp=35448983542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448983542&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2007.06.003

DO - 10.1016/j.autrev.2007.06.003

M3 - Article

C2 - 17967726

AN - SCOPUS:35448983542

VL - 7

SP - 52

EP - 58

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 1

ER -